| 000 | 00891nam a2200265Ia 4500 | ||
|---|---|---|---|
| 003 | OSt | ||
| 005 | 20220925195253.0 | ||
| 006 | a|||||r|||| 00| 0 | ||
| 007 | ta | ||
| 008 | 220923b |||||||| |||| 00| 0 eng d | ||
| 020 |
_a9780857932457 _c7687.4899999999998 |
||
| 037 |
_b5286, 02/09/2014, RAJKIRAN BOOK AGENCY _cGeneral Book |
||
| 040 |
_aRTL _cRTL _beng |
||
| 041 |
_2eng _aeng |
||
| 082 | _aX9(F56):(Z,2673), Q3 | ||
| 100 | _aDrexl Josef | ||
| 245 | 0 |
_cDrexl Josef; Lee Nari _aPharmaceutical innovation, competition and patent law _b A trilateral perspective |
|
| 260 |
_aCheltenham _bEdward Elgar _c2013 |
||
| 300 |
_aviii,337p. _ccm. |
||
| 500 | _aBibliography chapterwise | ||
| 650 | _aEconomics | ||
| 700 |
_a Lee Nari _9254010 |
||
| 942 |
_hX9(F56):(Z,2673), Q3 _cGB _2CC |
||
| 999 |
_c532417 _d532417 |
||